[{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ATTO-1310","moa":"IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Attovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Attovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"ATTO-1310","moa":"IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Attovia Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"6","companyTruncated":"Attovia Therapeutics \/ Goldman Sachs Alternatives"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Attovia Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Attovia Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ATTO-3712","moa":"SEMA3A","graph1":"Dermatology","graph2":"Phase I","graph3":"Attovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Attovia Therapeutics \/ Undisclosed"}]